2025
SJR Q1
JCR Q2 · 3,4
123 matched articles
SCIE
Journal detail
Thrombosis Research
- Publisher
- Elsevier Ltd
- Country
- United Kingdom · Western Europe
- Type
- journal
- ISSN
-
0049384818792472
Integrated evaluation
Scopus side is Scimago SJR; WoS side is Master Journal List + JCR/JIF. Sources are matched on ISSN. WoS / JCR metrics are available for 1997 and later years only.
WoS / JCR data covers 1997 onward.
Scopus
Scopus · Scimago
- SJR 1,046
- Quartile Q1
- H-Index 141
- Cites/doc 2,81
- Docs (3y) 838
- Cites (3y) 2.312
Clarivate
Web of Science · JCR · 2025
- JCR Q Q2
- JIF 3,4
- 5Y JIF 3,5
- JCI 0,76
WoS indexes
- SCIE
Subject classification
Categories (SJR)
- Hematology Q1
Areas
- Medicine
WoS categories
- Hematology | Peripheral Vascular Diseases
Yearly quartile comparison
Scimago (SJR) for all years; Clarivate (JCR / JIF / JCI) from 1997 onward. Latest year stays open; older years start collapsed.
WoS / JCR data covers 1997 onward.
| Year | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q1 | Q2 | 1,046 | 3,4 | 3,5 | 0,76 | Q2 | 141 |
| 2024 | Q2 | Q2 | 0,972 | 3,4 | 3,6 | 0,78 | Q2 | 134 |
| 2023 | Q1 | Q1 | 1,098 | 3,7 | 4,1 | 1,23 | Q1 | 134 |
| 2022 | Q1 | Q1 | 1,487 | 7,5 | 5,1 | 1,37 | Q1 | 134 |
| 2021 | Q1 | Q1 | 1,678 | 10,4 | 6,3 | 1,5 | Q1 | 134 |
| 2020 | Q1 | Q2 | 1,184 | 3,9 | 3,7 | 0,76 | Q2 | 134 |
| 2019 | Q2 | Q2 | 1,035 | 2,9 | 2,6 | 0,71 | Q2 | 134 |
| 2018 | — | Q2 | — | 3,3 | 2,8 | 0,69 | Q2 | — |
| 2017 | Q2 | Q2 | 1,096 | 2,8 | 2,6 | 0,66 | Q2 | 134 |
| 2016 | Q2 | Q2 | 1,059 | 2,6 | 2,6 | — | — | 134 |
| 2015 | Q2 | Q3 | 1,038 | 2,3 | 2,5 | — | — | 134 |
| 2014 | Q2 | Q3 | 0,989 | 2,4 | 2,5 | — | — | 134 |
| 2013 | Q2 | Q3 | 1,05 | 2,4 | 2,4 | — | — | 134 |
| 2012 | Q2 | Q2 | 1,133 | 3,1 | 2,8 | — | — | 134 |
| 2011 | Q2 | Q2 | 0,936 | 2,4 | 2,5 | — | — | 134 |
| 2010 | Q2 | Q2 | 0,96 | 2,4 | 2,4 | — | — | 134 |
| 2009 | — | Q2 | — | 2,4 | 2,3 | — | — | — |
| 2008 | — | Q2 | — | 2,4 | 2,3 | — | — | — |
| 2007 | — | Q3 | — | 2 | 2,1 | — | — | — |
| 2006 | — | Q3 | — | 2,1 | — | — | — | — |
| 2005 | — | Q2 | — | 2 | — | — | — | — |
| 2004 | — | Q3 | — | 1,5 | — | — | — | — |
| 2003 | — | Q2 | — | 1,7 | — | — | — | — |
| 2002 | — | Q2 | — | 1,5 | — | — | — | — |
| 2001 | — | Q3 | — | 1,4 | — | — | — | — |
| 2000 | — | Q3 | — | 1,3 | — | — | — | — |
| 1999 | — | Q3 | — | 1,2 | — | — | — | — |
| 1998 | — | Q3 | — | 1,2 | — | — | — | — |
| 1997 | — | Q2 | — | 1,5 | — | — | — | — |
JCR category quartile history
JCR / JCI quartile by year and category. 1997 and later.
WoS / JCR data covers 1997 onward.
| Year | Category | Edition | JCR Q (1997+) | JCI Q (1997+) | Rank |
|---|---|---|---|---|---|
| 2025 | HEMATOLOGY | SCIE | Q2 | Q2 | 34/103 |
| 2025 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | Q2 | 27/100 |
| 2024 | HEMATOLOGY | SCIE | Q2 | Q2 | 26/99 |
| 2024 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | Q2 | 27/98 |
| 2023 | HEMATOLOGY | SCIE | Q1 | Q1 | 23/97 |
| 2023 | PERIPHERAL VASCULAR DISEASE | SCIE | Q1 | Q1 | 21/96 |
| 2022 | HEMATOLOGY | SCIE | Q1 | Q1 | 14/79 |
| 2022 | PERIPHERAL VASCULAR DISEASE | SCIE | Q1 | Q1 | 9/68 |
| 2021 | HEMATOLOGY | SCIE | Q1 | Q1 | 11/78 |
| 2021 | PERIPHERAL VASCULAR DISEASE | SCIE | Q1 | Q1 | 6/67 |
| 2020 | HEMATOLOGY | SCIE | Q2 | Q2 | 30/76 |
| 2020 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | Q2 | 22/65 |
| 2019 | HEMATOLOGY | SCIE | Q2 | Q2 | 37/76 |
| 2019 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | Q2 | 27/65 |
| 2018 | HEMATOLOGY | SCIE | Q2 | Q2 | 27/73 |
| 2018 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | Q2 | 20/65 |
| 2017 | HEMATOLOGY | SCIE | Q2 | Q2 | 31/71 |
| 2017 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | Q2 | 30/65 |
| 2016 | HEMATOLOGY | SCIE | Q2 | — | 34/70 |
| 2016 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | — | 36/63 |
| 2015 | HEMATOLOGY | SCIE | Q3 | — | 44/70 |
| 2015 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | — | 38/63 |
| 2014 | HEMATOLOGY | SCIE | Q3 | — | 36/68 |
| 2014 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | — | 34/60 |
| 2013 | HEMATOLOGY | SCIE | Q3 | — | 35/68 |
| 2013 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | — | 34/65 |
| 2012 | HEMATOLOGY | SCIE | Q2 | — | 25/67 |
| 2012 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | — | 18/68 |
| 2011 | HEMATOLOGY | SCIE | Q3 | — | 39/68 |
| 2011 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | — | 31/68 |
| 2010 | HEMATOLOGY | SCIE | Q3 | — | 39/66 |
| 2010 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | — | 30/68 |
| 2009 | HEMATOLOGY | SCIE | Q3 | — | 31/61 |
| 2009 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | — | 27/61 |
| 2008 | HEMATOLOGY | SCIE | Q2 | — | 31/62 |
| 2008 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | — | 28/56 |
| 2007 | HEMATOLOGY | SCIE | Q3 | — | 35/63 |
| 2007 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | — | 29/54 |
| 2006 | HEMATOLOGY | SCIE | Q3 | — | 35/61 |
| 2006 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | — | 28/52 |
| 2005 | HEMATOLOGY | SCIE | Q2 | — | 30/60 |
| 2005 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | — | 29/51 |
| 2004 | HEMATOLOGY | SCIE | Q3 | — | 37/62 |
| 2004 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | — | 30/51 |
| 2003 | HEMATOLOGY | SCIE | Q2 | — | 31/62 |
| 2003 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | — | 25/52 |
| 2002 | HEMATOLOGY | SCIE | Q3 | — | 37/61 |
| 2002 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | — | 26/52 |
| 2001 | HEMATOLOGY | SCIE | Q3 | — | 32/59 |
| 2001 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | — | 29/50 |
| 2000 | HEMATOLOGY | SCIE | Q3 | — | 37/60 |
| 2000 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | — | 27/45 |
| 1999 | HEMATOLOGY | SCIE | Q3 | — | 34/60 |
| 1999 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | — | 23/44 |
| 1998 | HEMATOLOGY | SCIE | Q3 | — | 36/59 |
| 1998 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | — | 20/39 |
| 1997 | HEMATOLOGY | SCIE | Q2 | — | 29/59 |
| 1997 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | — | 17/38 |